EQL Pharma enters into a strategic licensing agreement with Adalvo for Mellozzan outside of Europe
EQL has entered into an exclusive license agreement for its product Mellozzan (melatonin) with Adalvo Ltd. for 89 countries outside Europe and the USA. Among the countries are large markets such as China, Brazil, Canada, Egypt and Japan. The agreement gives Adalvo exclusive rights to register, commercialise and distribute Mellozzan in these countries. If Adalvo decides to not pursue some countries the rights to Mellozzan for those specific countries shall be returned to EQL in a pre-defined reasonable timeframe.Adalvo is a B2B specialized pharmaceutical company which, via a very large